Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [2]. Core Views - The report highlights that the Chinese innovative drug sector is expected to experience new growth logic due to internal and external policy catalysts, suggesting a focus on undervalued small-cap pharmaceutical stocks [5][6]. Summary by Sections 1. Innovative Drugs and Industry Chain - **Sangfor Pharmaceutical**: Core products show steady growth, with innovative pipelines gradually yielding results. The PD-1/VEGF dual antibody AK112 has become the first to defeat K drug in head-to-head Phase III trials, enhancing the development heat for PD(L)-1/VEGF dual antibodies [10][11]. - **Kojin Pharmaceutical**: The CAR-T therapy shows significant potential, with its first product, CT053, approved for multiple myeloma treatment. Another product, CT041, is expected to submit NDA in mid-2025 [12][13]. - **Hotgen Biotech**: The SGC001 drug for acute myocardial infarction is progressing through clinical trials, with promising preclinical data indicating significant therapeutic effects [20][21]. - **Kangfang Biotech**: The company is advancing its IO+ADC strategy, with two dual antibodies already approved. It is collaborating with Pfizer to explore combination therapies for various solid tumors [30][34]. - **Kolin Biotech**: The company is expanding its international clinical trials with Merck, focusing on multiple cancer types [36][40]. 2. Market Performance Review - The pharmaceutical sector index fell by 2.7% from February 24 to February 28, 2025, underperforming the CSI 300 index by 0.5%. However, year-to-date, the sector has risen by 1.1%, outperforming the CSI 300 by 2.3% [43][44]. 3. Investment Strategy and Focus - The report suggests focusing on four main investment lines: 1) Oversold blue-chip stocks and Hong Kong stocks, 2) Companies with positive short-term changes and low price-to-book ratios, 3) Firms with solid fundamentals, and 4) Companies expected to show high growth in H2 2024 [7][8]. - Recommended stocks include Kangfang Biotech, Zai Lab, Kolin Biotech, and others [7]. 4. Industry Outlook - The report anticipates a recovery in the demand for innovative drugs, driven by supportive government policies and increased investment in the biotech sector. This recovery is expected to benefit upstream companies and CRO services [42].

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a positive outlook based on its innovative pipeline and potential in the heart failure market [5][65]. Core Insights - The company has a rich pipeline of innovative drugs, particularly the SGC001 antibody for acute myocardial infarction, which is expected to fill a significant clinical gap and has substantial domestic and international market potential [6][49]. - The company is actively expanding its innovative pipeline through subsidiaries focusing on nucleic acid drugs, antibody drugs, and probiotics, which are in various stages of development [7][20]. - The company has established itself as a leading brand in POCT (Point of Care Testing) and is integrating diagnostic and therapeutic strategies, particularly in the field of acute myocardial infarction [7][18]. Summary by Sections Market Performance - As of February 28, 2025, the closing price is 67.30 CNY, with a total market capitalization of 6,223.55 million CNY [3]. Financial Forecast - The company is projected to generate total revenues of 5.11 billion CNY in 2024, 6.02 billion CNY in 2025, and 7.08 billion CNY in 2026, with year-on-year growth rates of -5.61%, 17.85%, and 17.55% respectively [8][63]. - The net profit attributable to the parent company is expected to be -1.77 billion CNY in 2024, -0.68 billion CNY in 2025, and 0.43 billion CNY in 2026 [8][65]. Business Strategy - The company is leveraging its expertise in POCT to explore innovative drug development, establishing a multi-omics diagnostic technology platform and expanding into antibody and exosome drug fields [18][19]. - The SGC001 drug, developed for acute myocardial infarction, has received dual approval for clinical trials in both the US and China, highlighting its potential as a first-in-class treatment [48][49]. Competitive Position - The company is compared with peers in the POCT sector, such as Wanfu Biology and Jiuan Medical, indicating a stable POCT business and promising growth in innovative drug development [8][65].

证券代码：688068 证券简称：热景生物 北京热景生物技术股份有限公司 2025 年第一次临时股东大会会议资料 北京热景生物技术股份有限公司 2025 年第一次临时股东大会会议资料 2025 年 2 月 | 2025 | 年第一次临时股东大会会议须知 | 2 | | --- | --- | --- | | 2025 | 年第一次临时股东大会会议议程 | 4 | | 2025 | 年第一次临时股东大会会议议案 | 6 | 北京热景生物技术股份有限公司 2025 年第一次临时股东大会会议资料 北京热景生物技术股份有限公司 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会 的顺利进行，根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市 公司股东大会规则》以及《北京热景生物技术股份有限公司章程》、《北京热景生物 技术股份有限公司股东大会议事规则》等相关规定，北京热景生物技术股份有限公司 （以下简称"公司"）特制定本次股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作人员 将对出席会议者的身份进行必要的核对工 ...

Financial Performance - The total operating revenue for 2024 was 51,089.06 million CNY, a decrease of 7.62% compared to the previous year[4] - The net profit attributable to the parent company was -17,923.07 million CNY, a decline of 728.52% year-on-year[4] - The basic earnings per share fell by 725.81% to -1.94 CNY[5] - The company experienced a 317.82% increase in net profit attributable to the parent company after excluding non-recurring gains and losses, totaling -24,315.82 million CNY[4] - The weighted average return on equity decreased by 6.55 percentage points to -5.70%[5] Assets and Equity - The total assets at the end of the reporting period were 330,909.69 million CNY, down 7.35% from the previous year[5] - The equity attributable to the parent company decreased by 8.49% to 308,144.19 million CNY[5] Research and Development - The R&D investment for 2024 reached 11,276.71 million CNY, accounting for 22.07% of the operating revenue[7] - The company reported an investment loss of 4,763.16 million CNY from joint ventures due to increased R&D expenditures[7] Impairment and Competition - A total of 8,478.31 million CNY was recognized as impairment losses on operating assets due to intensified industry competition[7]

Core Viewpoint - The company reported a decline in revenue and a significant net loss for the year 2024, indicating challenges in its financial performance [1] Financial Performance - The total operating revenue for 2024 was 511 million yuan, representing a year-on-year decrease of 7.62% [1] - The net profit for the year was a loss of 179 million yuan, compared to a net profit of 28.52 million yuan in the same period last year [1] Research and Development - The company continued to invest in research and development for clinical immunodiagnostics and molecular diagnostics technology platforms [1] - The total R&D expenditure amounted to 113 million yuan, accounting for 22.07% of the operating revenue [1]

一、获得资质的具体情况 （一） 获得境外认证情况 | 序号 | 产品中文名称 | 产品英文名称 | 注册证号 | 分类 | 获批日期 | 有效期至 | 发证 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | （备案号） | | | | 国家 | | 1 | 糖化血红蛋白 测定试剂盒(磁 | Glycosylated Hemoglobin Chemiluminescence | / | / | 2025/3/1 | 2026/3/1 | IFCC (Internationa l Federation | | | | | | | | | of Clinical | | | 微粒化学发光 | Immunoassay Kit | | | | | Chemistry | | | 免疫分析法) | | | | | | and | | | | (CLIA) | | | | | Laboratory | | | | | | | | | Medicine ) | | 2 | 蛋白提取试剂 | Protein Extraction Kit | DE/CA22/ ...

证券代码：688068 证券简称：热景生物 公告编号：2025-013 北京热景生物技术股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/11/15 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 11 月 日~2025 年 | 15 | 2 | 月 14 | 日 | | 预计回购金额 | 万元 5,800 万元~10,000 | | | | | | 回购价格上限 | 元/股 82.69 | | | | | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | √为维护公司价值及股东权益 | | | | | | 实际回购股数 | 股 981,119 | | | | | | 实际回购股数占总股本比例 | 1.06% | | | | | | 实际回购金额 | 元 71,422,052 ...

北京热景生物技术股份有限公司 章 程 2025 年 2 月修订 1 | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 5 | | | 第一节 股份发行 5 | | | 第二节 股份增减和回购 6 | | | 第三节 股份转让 7 | | 第四章 | 股东和股东大会 8 | | | 第一节 股东 8 | | | 第二节 股东大会的一般规定 11 | | | 第三节 股东大会的召集 15 | | | 第四节 股东大会的提案与通知 17 | | | 第五节 股东大会的召开 18 | | | 第六节 股东大会的表决和决议 21 | | 第五章 | 董事会 26 | | | 第一节 董事 26 | | | 第二节 董事会 30 | | | 第三节 董事会专门委员会 35 | | 第六章 | 总经理及其他高级管理人员 37 | | 第七章 | 监事会 39 | | | 第一节 监事 39 | | | 第二节 监事会 39 | | 第八章 | 财务会计制度、利润分配和审计 41 | | | 第一节 财务会计制度 41 | | | 第二节 内部审计 46 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-010 北京热景生物技术股份有限公司 关于预计公司 2025 年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否需要提交股东大会审议：否 日常关联交易对上市公司的影响：公司与关联方所发生的日常关联交易 属于公司从事生产经营活动的正常业务往来，符合正常商业逻辑及公平原则，在 双方平等协商达成的交易协议的基础上实施，交易条件及定价公允，并按照相关 规定履行批准程序，不存在损害公司和股东利益的情形。进行上述相关日常关联 交易对公司主营业务不构成重大影响。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 北京热景生物技术股份有限公司（以下简称"公司"）于 2025 年 2 月 14 日召开第三届董事会第二十六次会议，审议通过了《关于预计公司 2025 年度日 常关联交易的议案》，同意 2025 年度预计日常关联交易总额为人民币 3,850.00 万元，较上一年度预计金额增加人民币 1,050.00 万元。董事会在审 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-009 北京热景生物技术股份有限公司 关于增加公司经营范围暨修订《公司章程》并办理 工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京热景生物技术股份有限公司（以下简称"公司"）于 2025 年 2 月 14 日召开了第三届董事会第二十六次会议，审议通过了《关于增加公司经营范围暨 修订<公司章程>并办理工商变更登记的议案》，该议案尚需提交公司股东大会审 议。现将具体情况公告如下： 根据前述新增公司经营范围相关内容，拟修订《公司章程》相应条款，具体 内容如下： | 原条款 | 修订后的条款 | | --- | --- | | 第十四条 经依法登记，公司的经营范围为：一 | 第十四条 经依法登记，公司的经营范围为：一 | | 般项目：技术服务、技术开发、技术咨询、技术 | 般项目：技术服务、技术开发、技术咨询、技术 | | 交流、技术转让、技术推广；货物进出口；技术 | 交流、技术转让、技术推广；货物进出口；技术 | | 进出口；进出口代理； ...